IP Library Granted Patent US 12691066
Granted Patent B2
US 12691066 · App. 18/591,795 · Granted Jul 28, 2026

Dual-targeting biomimetic liposome with elemene (ELE) and cabazitaxel (CTX), and preparation method and use thereof

Inventors: Tian Xie (Hangzhou, CN); Yiying Zeng (Hangzhou, CN); Jie Li (Hangzhou, CN); Zhaowu Zeng (Hangzhou, CN)
Assignee: HANGZHOU NORMAL UNIVERSITY
A61K9/1271A61K31/015A61K31/337A61K47/10A61K47/24A61K47/42A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691066
App. No.
18/591,795
Granted
Jul 28, 2026
Kind
B2
Abstract

The present disclosure provides a dual-targeting biomimetic liposome with elemene (ELE) and cabazitaxel (CTX), where each 100 mL of the dual-targeting biomimetic liposome with ELE and CTX includes 0.15 g to 0.75 g of the ELE, 0.5 mL to 2.5 mL of absolute ethanol, 0.015 g to 0.07 g of the CTX, 0.25 g to 1 g of oil, 0.25 g to 1 g of a polyethylene glycol (PEG) derivative, 1 g to 5 g of a phospholipid, 0.05 g to 0.2 g of cholesterol, 0.025 g to 0.1 g of distearoyl phosphatidylethanolamine-polyethylene glycol 2000-transferrin (DSPE-PEG2000-Tf), 0.005 g to 0.025 g of a tumor cell membrane protein (CMP), and water as a balance.

Claims (8)

1 . A dual-targeting biomimetic liposome with elemene (ELE) and cabazitaxel (CTX), wherein each 100 mL of the dual-targeting biomimetic liposome with ELE and CTX comprises 0.15 g to 0.75 g of the ELE, 0.5 mL to 2.5 mL of absolute ethanol, 0.015 g to 0.07 g of the CTX, 0.25 g to 1 g of oil, 0.25 g to 1 g of a polyethylene glycol (PEG) derivative, 1 g to 5 g of a phospholipid, 0.05 g to 0.2 g of cholesterol, 0.025 g to 0.1 g of distearoyl phosphatidylethanolamine-polyethylene glycol-transferrin (DSPE-PEG-Tf), 0.005 g to 0.025 g of a tumor cell membrane protein (CMP), and water as a balance.

2 . The dual-targeting biomimetic liposome with ELE and CTX according to claim 1 , wherein the oil is one or more selected from the group consisting of medium-chain triglyceride (MCT), soybean oil, palm oil, coconut oil, fish oil, hydrogenated oil, and animal oil.

3 . The dual-targeting biomimetic liposome with ELE and CTX according to claim 1 , wherein the phospholipid is one or more selected from the group consisting of soybean phospholipid, egg yolk phospholipid, hydrogenated phospholipid, and synthetic phospholipid.

4 . The dual-targeting biomimetic liposome with ELE and CTX according to claim 1 , wherein the PEG derivative is selected from the group consisting of D-α-tocopherol polyethylene glycol succinate (TPGS) and DSPE-PEG.

5 . The dual-targeting biomimetic liposome with ELE and CTX according to claim 1 , wherein the DSPE-PEG-Tf is selected from the group consisting of DSPE-PEG2000-Tf, DSPE-PEG3000-Tf, DSPE-PEG4000-Tf, and DSPE-PEG5000-Tf.

6 . The dual-targeting biomimetic liposome with ELE and CTX according to claim 1 , further comprising an osmotic pressure regulator.

7 . The dual-targeting biomimetic liposome with ELE and CTX according to claim 6 , wherein the osmotic pressure regulator is one or more selected from the group consisting of glycerol, glucose, sucrose, trehalose, maltose, and mannitol.

8 . The dual-targeting biomimetic liposome with ELE and CTX according to claim 1 , wherein the ELE and the CTX are at a mass ratio of 10:1.